Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Cinclus Pharma's data presented at UEG

The results of a phase 1 study of the acid inhibition effect of Cinclus Pharma's P-CAB linaprazan glurate will be presented at the leading congress United European Gastroenterology Week (UEG) 12 – 15 October 2024. The study results show that linaprazan glurate has a very rapid and effective acid inhibition already 90 minutes after first dosing. The best doses provide near complete acid control (pH>4) over all 24 hours of the day.

"Since only leading and new research is selected by the UEG, we are incredibly proud that our data is presented. It indicates that our P-CAB linaprazan glurate is very interesting for gastroenterology. The data we present provide very good conditions to heal all patients suffering from eGERD, including the most difficult patients who are also our primary target group. We are moving forward with the goal of bringing about a paradigm shift in the treatment of gastric acid related diseases," said Christer Ahlberg, CEO of Cinclus Pharma.

The abstract Pharmacokinetics and pharmacodynamics of Linaprazan glurate after multiple oral doses up to 14 days in healthy subjects is presented on Sunday, October 13, 16:18 - 16:30.

Datum 2024-09-24, kl 08:30
Källa MFN